Although pancreatic cancer (PC) continues to be a formidable disease,
numerous treatment strategies are evolving that we hope will result in
improved patient survival. To prolong the survival of patients with P
C, it is essential to detect PC at the earliest stage possible and to
develop effective nonsurgical treatments for this disease. The current
strategies for the early diagnosis of PC include the development of d
iagnostic modalities and screening programs for the early detection of
PC and the determination of high-risk groups for PC. K-ras mutations
in pancreatic juice obtained endoscopically have been studied recently
in association with the early diagnosis of PC, although the interpret
ation of the presence of a mutated K-ras gene requires caution. The ro
le of the current nonsurgical treatments for PC has been limited. Iden
tification of an effective new chemotherapeutic agent is a high priori
ty, and the enrollment of patients with PC with metastatic disease int
o well-designed clinical trials is essential. New targets for therapy
based on the understanding of the molecular biology of PC may provide
avenues for future trials. We must continue to search actively for mor
e accurate methods of diagnosis and more effective methods of treatmen
t for PC.